NCT03315741View on ClinicalTrials.gov

The Safety and Tolerability of Pirfenidone for BOS After HCT

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

February 27, 2022

Study Completion Date

April 27, 2022

Conditions

Bronchiolitis ObliteransGraft Vs Host Disease

Interventions

DRUG

Pirfenidone 267 MG [Esbriet]

Tolerability of drug

Trial Locations (1)

94304

Stanford University School of Medicine, Palo Alto

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT03315741 - The Safety and Tolerability of Pirfenidone for BOS After HCT | Biotech Hunter | Biotech Hunter